Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)
This study has been completed.
Study NCT00442845 Information provided by Pfizer
First Received on February 28, 2007. Last Updated on April 4, 2007
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Coronary Arteriosclerosis
Diabetes Mellitus, Type 2
Cerebrovascular Accident
Dyslipidemia
Peripheral Vascular Disease
Additional conditions recognized in this trial
Arteriosclerosis
Cerebral Infarction
Coronary Artery Disease
Diabetes Mellitus
Dyslipidemias
Myocardial Ischemia
Peripheral Arterial Disease
Peripheral Vascular Diseases
Stroke
Vascular Diseases
More general conditions related to this trial
Arterial Occlusive Diseases
Atherosclerosis
Brain Diseases
Brain Infarction
Brain Ischemia
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Coronary Disease
Endocrine System Diseases
Glucose Metabolism Disorders
Heart Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Nervous System Diseases
Interventions listed in this trial
Atorvastatin (Lipitor)
Additional drug interventions recognized in this trial
Atorvastatin
More general drug interventions related to this trial
Anticholesteremic Agents
Antimetabolites
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Pfizer
Back to top of Main Content
